文献速递神经肿瘤脑血管病外科神经重症

MAPK通路靶向治疗相关瘤内及颅内出血:系统综述与机制整合

Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis.
PubMed 文献 · J Neurooncol · 2026-07-15

该系统综述检索PubMed/MEDLINE与Embase至2026年5月,评估MAPK通路抑制剂(BRAF、MEK及II型RAF抑制剂)相关瘤内或颅内出血。结果显示不同药物的CNS出血信号存在异质性:达拉非尼方案在黑色素瘤脑转移中ICH率为6%,tovorafenib在BRAF变异pLGG中任何级别出血达42%、瘤内出血9%。BRAF抑制剂联合立体定向放射外科较单纯放疗ICH风险升高约3倍。

要点

  • MAPK通路抑制剂在多种肿瘤中呈现一致的CNS出血信号,但发生率因药物、人群和判定方法而异。
  • tovorafenib治疗BRAF变异pLGG的瘤内出血在汇总FDA安全性人群中为9%。
  • BRAF抑制剂联合立体定向放射外科较单纯放疗ICH风险升高约3倍(OR 3.16)。

核心结论

  • MAPK通路抑制剂与一致的但异质性的CNS出血信号相关。
  • 报告发生率从成人黑色素瘤达拉非尼方案症状性ICH<1%到儿童tovorafenib汇总安全性人群瘤内出血9%不等。
  • 需标准化定义、CNS特异性CTCAE采集及前瞻性影像监测以明确真实发生率与风险。

研究设计与样本

  • 系统综述,检索PubMed/MEDLINE与Embase自建库至2026年5月,并补充FDA处方信息。
  • 纳入报告MAPK通路靶向药物相关瘤内或颅内出血的研究,涵盖多种肿瘤类型。
  • 因报告定义和研究设计异质性,结果采用叙述性综合。
  • 该系统综述未在PROSPERO前瞻性注册。

主要发现

  • 达拉非尼单药方案在黑色素瘤脑转移中ICH率为6%(BREAK-MB)。
  • COMBI-MB联合方案中发生致命性出血的比例为0.8%。
  • tovorafenib治疗BRAF变异pLGG(n=137)任何部位任何级别出血发生率为42%,3-4级出血7例(5%),另有1例致命性5级瘤内出血。
  • 重叠的FDA标签汇总安全性人群(N=140)中瘤内出血报告率为9%。
  • BRAF抑制剂联合立体定向放射外科较单纯放疗ICH风险升高约3倍(OR 3.16;95%CI 1.43-6.96)。

关键数值与推荐

  • 达拉非尼为基础方案在黑色素瘤脑转移中ICH率:单药6%,联合方案致命性出血0.8%。
  • tovorafenib在BRAF变异pLGG中任何级别出血42%,3-4级5%,致命性瘤内出血1例。
  • FDA汇总安全性人群(N=140)中tovorafenib相关瘤内出血9%。
  • BRAF抑制剂联合立体定向放射外科ICH风险OR 3.16(95%CI 1.43-6.96)。

临床怎么用

  • 对接受MAPK通路抑制剂尤其是tovorafenib的BRAF变异pLGG患者,应关注瘤内及颅内出血风险。
  • 成人黑色素瘤脑转移使用达拉非尼方案时需警惕ICH,联合立体定向放射外科时风险进一步升高。
  • 建议采用标准化出血定义和CNS特异性CTCAE采集,并考虑前瞻性影像监测。

局限性

  • 报告定义和研究设计异质性大,无法进行定量合并。
  • 出血判定方法不同(主动影像监测与临床报告)影响发生率估计。
  • 该系统综述未在PROSPERO前瞻性注册。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: MAPK-pathway inhibitors including BRAF, MEK, and type II RAF inhibitors are now integral to treatment of pediatric low-grade glioma (pLGG), BRAF V600-mutant glioma, NF1-associated tumors, and melanoma brain metastases. Intratumoral and intracranial hemorrhage has emerged as a clinically relevant safety signal, but drug-specific incidence estimates, phenotypic definitions, and contributing mechanisms remain incompletely characterized. We systematically reviewed the evidence and synthesized contributing mechanisms. METHODS: We performed a systematic review of PubMed/MEDLINE and Embase from database inception through May 2026, supplemented by FDA prescribing information, to identify studies reporting intratumoral or intracranial hemorrhage with MAPK-pathway targeted agents across tumor types. Results were synthesized narratively given heterogeneity in reporting definitions and study designs. RESULTS: CNS hemorrhage signals were identified across agents. Dabrafenib-based regimens in melanoma brain metastases produced ICH rates of 6% (BREAK-MB monotherapy) and a fatal hemorrhage in 0.8% (COMBI-MB combination). In the phase 2 FIREFLY-1 trial of tovorafenib in BRAF-altered pLGG (n = 137), any-site hemorrhage of any grade occurred in 42% of patients with grade 3-4 hemorrhage in 7 patients (5%) and, separately, one fatal grade 5 intratumoral hemorrhage; in the overlapping pooled FDA-label safety population (N = 140), intratumoral hemorrhage specifically was reported in 9%. Combining BRAF inhibitors with stereotactic radiosurgery was associated with 3-fold higher odds of ICH versus radiosurgery alone (OR 3.16; 95% CI 1.43-6.96). CONCLUSION: MAPK-pathway inhibitors are associated with a consistent but heterogeneous CNS hemorrhage signal. Reported incidence varies by agent, population, and hemorrhage ascertainment method (active imaging-based surveillance versus clinical reporting), from < 1% symptomatic ICH with dabrafenib in adult melanoma to 9% intratumoral hemorrhage in the pooled pediatric tovorafenib safety population. Standardized definitions, CNS-specific CTCAE capture, and prospective imaging surveillance are needed to define true incidence and risk as MAPK-directed therapy expands in neuro-oncology. REGISTRATION: This systematic review was not prospectively registered in PROSPERO.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Damodharan S, Calderon A, Abdelbaki MS, et al. Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis. J Neurooncol. 2026. PMID: 42455393. doi:10.1007/s11060-026-05714-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。